Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents

摘要

This invention relates to compositions and methods useful for treating or reducing the advancement, severity or effects of neoplasia by the administration of at least two or more lymphotoxin beta receptor (LT-beta receptor) activating agents where at least one LT-beta receptor activating agent is an anti-LT-beta receptor antibody.